You searched for "Cisplatin"

604 results found

COOL therapy for cisplatin-induced hearing loss

Cisplatin is a commonly used cancer therapy, with nearly 50% of patients undergoing chemotherapy receiving cisplatin as part of their regimen [1]. Depending on the dose, incidence of hearing loss has been reported as 12-100% in adults, and 37-94% in...

OTO-104 in noise-induced and cisplatin-induced hearing loss

These two animal studies report on potential new applications for intra-tympanic OTO-104, a slow-release hydrogel formulation of dexamethasone that is currently being used in a Europe-wide randomised trial for Ménière’s disease. In the first paper, guinea pigs were given a...

Pomegranate juice as an otoprotective agent

Chemotherapeutic agents such as cisplatin, given alongside irradiation, offer a survival advantage in head and neck cancer. Some patients often complain bitterly about side-effects of their treatment, one of which is ototoxicity. In this paper, the authors propose the use...

Paediatric hearing following chemotherapy

This study examined the effect of platinum compounds on hearing in 104 children with solid tumours. As would be expected, this group was heterogeneous and included a range of ages, tumour types, chemotherapeutic agents and dosing regimens. Age-appropriate audiometry was...

Unanswered questions in adult ototoxicity associated with platinum-based chemotherapy

Do the potential side-effects on hearing and tinnitus need to be a ‘necessary evil’ of platinum-based chemotherapy? How strong is our evidence base when offering advice to patients and fellow clinicians? David Baguley and his team from the University of...

Audiology in this issue...Prevention

Alex Griffiths-Brown, BSc(Hons), MRes, Audiologist, The Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK. E: alex.griffiths-brown@nhs.netTwitter: @griffithsbrown1 'Prevention is better than cure’ is an adage that is attributed to the Dutch philosopher, Desiderius Erasmus, in around 1500. It is a...

Predicting which oropharyngeal SCC HPV-positive patients should avoid de-escalated treatment

This study is timely for many reasons and raises very important questions in the management of the current rise in HPV-positive patients with oropharyngeal cancer (OPC). The uniqueness of this group within head and neck cancer in terms of favourable...

Precision and personalised genomic and epigenomic medicine in audiology/hearing loss

A detailed look at the pathogenesis of acquired hearing loss due to exposure to ototoxicity during pregnancy or shortly after birth. Insights from genomic medicine have shown that, along with environmental factors causing epigenetic alterations, hearing loss may be caused...

Platinum-based chemotherapy, tinnitus and hearing loss

Fortunately, the five-year survival rate of adult cancers is increasing. However, we are seeing for the first time the lasting effects of cancer treatments on people. As more people live with the long-term effects of treatment, such as chemotherapy, it is imperative to understand the impact it has on quality of life.

Audiological monitoring in ototoxicity - Are we doing enough?

In this article Ghada Al-Malky explores the dichotomy of life-saving, yet hearing loss-causing medication, and questions whether the hearing healthcare community is doing enough to prevent preventable hearing loss. Ototoxicity is the damage to hearing and / or balance functions...

The search for pharmacological treatments for hearing loss and tinnitus

Where are we in our search for a hearing restoration grail? Nicola Robas leads us through the map pieces discovered in creating a pharmaceutical answer to hearing loss and tinnitus. Together, hearing loss and tinnitus affect over one in six...

Could social isolation be a factor in the link between hearing loss and dementia?

In 1802, Beethoven wrote to his brothers Carl and Johann about his hearing loss: “You men who think or say that I am malevolent, stubborn, or misanthropic, how greatly do you wrong me. You do not know the secret cause...